Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Verona Pharma plc (NASDAQ:VRNA) is one of the best multibagger stocks according to hedge funds. On July 9, 2025, Merck & Co.

Merck has had a successful track record of beating estimates, having surpassed EPS expectations 88% of the time and beating ...

Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of ...

Merck is undervalued with strong growth, profitability, and credit strength despite CDMO challenges, offering compelling ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...